Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

[Anti-tumor necrosis factor drug therapy: The usefulness of monitoring drug levels and anti-drug antibodies in clinical practice].

García Ruiz de Morales JM, Pascual-Salcedo D, Llinares Tello F, Valor Méndez L.

Med Clin (Barc). 2016 Nov 4;147(9):410-416. doi: 10.1016/j.medcli.2016.04.002. Spanish. No abstract available.

PMID:
27216221
2.

Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis.

López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Filloy JA, Magro C, Tejera-Segura B, Ramírez Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Mínguez Sánchez MD, Gómez-Vaquero C, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2016 Aug 18;6:31979. doi: 10.1038/srep31979.

3.

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.

Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G.

Scand J Rheumatol. 2016 Jul 20:1-8. [Epub ahead of print]

PMID:
27440258
4.

Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.

Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62.

PMID:
27214767
5.

Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study.

Alcobendas R, Rodríguez-Vidal A, Pascual-Salcedo D, Murias S, Remesal A, Diego C, Merino R.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5):955-956.

PMID:
27156742
6.

Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.

Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, Plasencia C, Balsa A, Llinares-Tello F, Rosas J, Torres N, Martínez A, Nagore D.

Ann Rheum Dis. 2016 Sep;75(9):1693-6. doi: 10.1136/annrheumdis-2015-208684.

PMID:
26965981
7.

Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.

Plasencia C, Jurado T, Villalba A, Peitedado D, Casla MT, Nuño L, Bonilla MG, Martínez-Feito A, Martín-Mola E, Pascual-Salcedo D, Balsa A.

Front Med (Lausanne). 2015 Oct 8;2:71. doi: 10.3389/fmed.2015.00071.

8.

Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.

Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuño L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D.

J Rheumatol. 2015 Sep;42(9):1638-46. doi: 10.3899/jrheum.141128.

PMID:
26178279
9.

Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases.

Martín S, del Agua AR, Torres N, Pascual-Salcedo D, Plasencia C, Ruiz-Argüello B, Martínez A, Navarro R, Nagore D.

Clin Chem Lab Med. 2015 Oct;53(11):e297-9. doi: 10.1515/cclm-2015-0266. No abstract available.

PMID:
25945722
10.

Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.

Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Cañete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Fernández-Nebro A, Ordóñez MC, Alegre-Sancho JJ, Narváez J, Navarro-Sarabia F, Moreira V, Valor L, García-Portales R, Marquez A, Martin J, Gómez-Reino JJ, Gonzalez A.

Pharmacogenomics J. 2016 Apr;16(2):137-40. doi: 10.1038/tpj.2015.29.

PMID:
25896535
11.

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernández-Nebro A, Ordóñez Mdel C, Narváez J, Cañete JD, Marquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Caliz R, Ferrer MA, Garcia-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martin J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., Gómez-Reino JJ, Gonzalez A.

Arthritis Res Ther. 2015 Mar 18;17:63. doi: 10.1186/s13075-015-0571-z.

12.

Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Corrales A, Llorca J, González-Juanatey C, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Biomed Res Int. 2015;2015:318364. doi: 10.1155/2015/318364.

13.

Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome.

Rodríguez-Sanz A, Martínez-Sánchez P, Prefasi D, Fuentes B, Pascual-Salcedo D, Blanco-Bañares MJ, Díez-Tejedor E.

Autoimmunity. 2015;48(5):275-81. doi: 10.3109/08916934.2014.988329.

PMID:
25434364
14.

Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice.

Kneepkens EL, Plasencia C, Krieckaert CL, Pascual-Salcedo D, van der Kleij D, Nurmohamed MT, López-Casla MT, Wieringa R, Rispens T, Wolbink G.

Ann Rheum Dis. 2014 Dec;73(12):2217-9. doi: 10.1136/annrheumdis-2014-205983. No abstract available.

PMID:
25261580
15.

Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis.

Genre F, López-Mejías R, García-Bermúdez M, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

PLoS One. 2014 Sep 3;9(9):e106823. doi: 10.1371/journal.pone.0106823.

16.

Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience.

Murias S, Alcobendas R, Pascual-Salcedo D, Remesal A, Peralta J, Merino R.

Rheumatology (Oxford). 2014 Nov;53(11):2124-6. doi: 10.1093/rheumatology/keu305. No abstract available.

PMID:
25102859
17.

Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Llorca J, González-Juanatey C, Corrales A, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Arthritis Res Ther. 2014 Jul 10;16(4):R146. doi: 10.1186/ar4608.

18.

Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis.

López-Mejías R, Genre F, García-Bermúdez M, Ubilla B, Castañeda S, Llorca J, González-Juanatey C, Corrales A, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Mediators Inflamm. 2014;2014:756279. doi: 10.1155/2014/756279.

19.

Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis.

Márquez A, Ferreiro-Iglesias A, Dávila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E, Moreno-Ramos MJ, García-Portales R, Navarro F, Moreira V, Magro C, Caliz R, Ferrer MA, Alegre-Sancho JJ, Joven B, Carreira P, Balsa A, Vasilopoulos Y, Sarafidou T, Cabeza-Barrera J, Narvaez J, Raya E, Cañete JD, Fernández-Nebro A, Ordóñez Mdel C, de la Serna AR, Magallares B, Gomez-Reino JJ, González A, Martín J.

Arthritis Res Ther. 2014 Mar 11;16(2):R66. doi: 10.1186/ar4504.

20.

Single-nucleotide polymorphisms at the 9p21.3 genomic region not associated with the risk of cardiovascular disease in patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Pascual-Salcedo D, Balsa A, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

Tissue Antigens. 2013 Dec;82(6):405-9. doi: 10.1111/tan.12227.

PMID:
24498997
Items per page

Supplemental Content

Loading ...
Support Center